Respiratory Infections

A study by Shikha Garg, MD, MPH, and her team with the US Centers for Disease Control and Prevention boosts the evidence base for the benefit of influenza vaccination.

According to the WHO’s latest Global TB Report, more than 7 million individuals received treatment for the disease in 2018, but funding gaps could stall progress toward ending TB by 2030.

Angela Campbell, MD, MPH, details a study on influenza vaccine effectiveness in children with respiratory illness.

NEJM study suggests testing everyone, regardless of symptoms, can reduce prevalence.

Helen Chu, MD, MPH, discussed the "Seattle Flu Study" with Contagion at IDWeek 2019.

The most common presentation for pediatric invasive aspergillosis patients was a pulmonary infection.

A new study delves into the debate of N95 respirators versus surgical masks for seasonal influenza and other respiratory illnesses.

Natural disasters like hurricanes can have implications for public health, including a heightened risk of infectious diseases.

As the summer comes to a close, our editorial team is looking back at the top FDA approvals of 2019 to date and looking ahead at what is left on the docket this year.

Investigators with Seqirus presented findings from a handful of studies on a MF59 adjuvanted influenza vaccine at the Options for the Control of Influenza (OPTIONS X) Conference in Singapore.

Two-thirds of patients hospitalized with pneumonia received an excess duration of antibiotic treatment, and the results can be detrimental.

Three children in US Customs and Border Protection custody have died since December 2018, partially due to influenza. Now, the infectious disease community is rallying for vaccination for migrants in detention facilities.

The HITS consortium provided a wealth of knowledge on infection prevention topics, but also served as an environment for frank and honest discussions regarding Legionella management.

A UK study details a new way to prevent Legionnaires' disease and save energy.

Leslie Tari, PhD, discusses the treatment and prevention of influenza.

Investigators say that 12 weeks following vaccination neutralizing antibodies remained 5- to 10-fold above baseline levels in all vaccine dosage groups.

Marin Kollef, MD, discusses what makes the 3-gram dose regimen of ceftolozane/tazobactam unique.